American Society of Hematology (ASH) 2012 Converage

ASH 2012

ASH: Pomalidomide + Low-Dose Dexamethasone Improves PFS, OS in Relapsed/Refractory Multiple Myeloma

Pomalidomide plus low-dose dexamethasone significantly improved progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory multiple myeloma vs high-dose dexamethasone alone and “should be considered as a new treatment option for these patients” who have exhausted lenalidomide and bortezomib, a study presented during the 54th American Society of Hematology Annual Meeting and Exposition recommended.

ASH: Superior Disease-Free Survival in Elderly AML Patients Undergoing High-dose Cytarabine-based Therapy

Elderly patients undergoing consolidation therapy for acute myeloid leukemia (AML) using a modified regimen of high-dose cytarabine plus the anthracycline daunorubicin experienced prolonged disease-free survival (DFS) times, according to a study presented during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH: Patient Factors Affect Outcomes Among Older AML Patients Treated with Decitabine

Patient age, baseline bone marrow blasts, platelet and WBC counts, and geography all modulate overall survival (OS) benefits associated with decitabine for patients diagnosed with acute myeloid leukemia (AML) at age ≥65 years, according to analysis of data from a multinational Phase 3 trial presented during the 54th American Society of Hematology (ASH) Annual Meeting and Exposition.

ASH: Azacitidine-Containing Induction Regimens in High-Risk AML

Induction therapy with either idarubicin plus cytarabine plus etoposide (ICE), or idarubicin plus etoposide followed by azacitidine (AZA-after), yielded comparable rates of complete remission (CR) among patients with high-risk acute myeloid leukemia (AML), according to a study presented during the 54th American Society of Hematology (ASH) Annual Meeting and Exposition.

ASH: Adding Intrathecal Rituximab to R-DHAP + ASCT Feasible for Relapsed CNS Lymphoma

Combining the standard R-DHAP regimen plus autologous stem cell transplantation (ASCT) for relapsed diffuse large B-cell lymphoma (DLBCL) with intrathecal rituximab and high-dose IV methotrexate (MTX) is feasible for the treatment of secondary central nervous system (CNS) lymphoma, investigators reported during the 54th American Society of Hematology Annual Meeting and Exposition.

Next post in ASH 2012